The mutation pattern of KRAS provides guidance of individualized treatment, and the KRAS wild‐type colorectal cancer patients can benefit from treatment with anti‐epidermal growth factor cetuximab.6, 7. This evidence concerns the gene KRAS and colorectal cancer.